However, the study of HMGB1 in NSCLC is still in its early stage, and there is a lack of systematic reports on the detailed roles of HMGB1 in cisplatin resistance in NSCLC, as well as the correlation between HMGB1 and various clinicopathological features. This evidence concerns the gene HMGB1 and non-small cell lung carcinoma.